

PATENT

ATTORNEY DOCKET NO.
WAX017-185360C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Continuation of:

In re	: Application of	: Group Art Unit 1616
	: T. Zhang	: Examiner: J. Pak
	: Appln. No.	: 08/702,011
	: Filed	: August 23, 1996
	: For	: AN INJECTABLE : COMPOSITION FOR CANCER : TREATMENT
		: Attorney Docket : No.: 3129-4000

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

SIR:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98 and to the duty of disclosure set forth in 37 C.F.R. § 1.56, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the attached pages. The references cited in this Information Disclosure Statement were cited in U.S. Serial No. 08/702,011, the patent application to the present application. Accordingly, these references are not submitted herewith.

Express Mailing Label No. EL952440943US

Date of Deposit November 17, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Renee Conti

ATTY. DOCKET NO. WAX017-185360C

Although the information submitted herewith may be "material" to the Examiner's consideration of the subject application, this submission is not intended to constitute an admission that such information is "prior art" as to the claimed invention.

In accordance with C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

This Information Disclosure Statement is being filed along with above-referenced application.

No fee or certification is required. 37 C.F.R. § 1.97(b).

Dated: 11/17/03

Respectfully submitted,



Eric A. Dichter, Reg. No. 41,708
Wolf, Block, Schorr and Solis-Cohen LLP
1650 Arch Street - 22nd Floor
Philadelphia, PA 19103
(215) 977-2169
Attorney for Applicant

The Commissioner for Patent is
hereby authorized to charge payment or
credit overpayment to Deposit Account
No. 232820 of any fees associated with
this communication.

U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (Rev. 2-32) Information Disclosure Statement by Applicant	ATTY. DOCKET NO.	SERIAL NO
	WAX017-185360C	To Be Assigned
	APPLICANT Zhang, Ting-Dong	
FILING DATE To Be Assigned	GROUP To Be Assigned	

U.S. PATENT DOCUMENTS

Exmr Initial		Document Number	Date	Name	Class	Sub Class	Filing Date

FOREIGN PATENT DOCUMENTS

Exmr Initial		Document Number	Date	Country	Class	Sub Class	Translation YES NO
		95/01789	1/19/95	WO - PCT			

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

		Study on Chronic Toxicity of Arsenic Trioxide in Rats with Special Reference to the Liver Damages by Noburu Ishinishi, Masako Tomita and Akira Hisanaga at the Department of Hygiene, Faculty of Medicine, Kyushu University, Fukuoka, Japan
		Suehiro Shimotsuura, Studies on the Antineoplastic Actions of As ₂ O ₃ by Department of Pharmacology, Tokyo Dental College (1986) (English Translation)
		IPCS International Programme on Chemical Safety, Environmental Health Criteria 18 - Arsenic, published under the joint sponsorship of the United Nations Environment Programme, the International Labour Organisation, and the World Health Organization - World Health Organization, Geneva, pp. 76-146, 1981
		IPCS International Programme on Chemical Safety Health and Safety Guide No. 70 - Inorganic Arsenic Compounds Other Than Arsine Health and Safety Guide - World Health Organization, Geneva 1992
		Huang, S.L. et al., Chinese J. Hematol., Vol. 16, 1995, pages 26-28

Examiner	Date Considered
----------	-----------------

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Rev. 2-32) U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Information Disclosure Statement by Applicant	ATTY. DOCKET NO.	SERIAL NO
	WAX017-185360C	To Be Assigned
	APPLICANT Zhang, Ting-Dong	
FILING DATE To Be Assigned	GROUP To Be Assigned	

		Kwong, Y.L. et al., "Delicious Poison: Arsenic Trioxide for the treatment of Leukemia," Blood, Vol. 89(9), 1997, pages 3487-3488.
		Shen, Zhi-Xiang et al., "Use of Arsenic Trioxide (As ₂ O ₃) in the treatment of Acute Promyelocytic Leukemia (APL) . . ." Blood, Vol. 89(9), 1997, page 3354.
		Fluka 1995/96 Catalog, page 152-153 - July, 1995.
		USP dictionary of USAN and International Drug Names, United States Pharmacopeial Conventions, Inc., Rockville, MD, page 59. November, 1994
		Zhang Peng et al., "Treatment of acute promyelocytic leukemia with intravenous arsenic trioxide," Chinese Journal of Hematology, Vol. 17, No. 2, pages 58-60. February, 1996
		Guo-Qiang Chen et al., "In vitro studies on cellular and molecular mechanisms of arsenic trioxide . . ." Blood, Vol. 88, No. 3, pages 1052-61. August 1, 1996
		Shibuya, "Experimental arsenous oxide poisoning," Tokyo Jikeikai Ika Daigaku Zasshi, Vol. 86, No. 4, pages 563-75. 1971
		Reichl et al., "Effect of arsenic on cellular metabolism after single or repeated injection in guinea pigs," Arch. Toxicol., Suppl. 13, pages 363-65. 1989
		Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, pages 1570-80. 1990
		Arsenic, Environmental Health Criteria 18, Geneva: WHO, 1981
		Inorganic Arsenic Compounds Other Than Arsine Health and Safety Guide Health and Safety Guide No. 70, WHO, Geneva, 1992
		Ishinishi N. et al. Study on Chronic Toxicity of Arsenic Trioxide in Rats with Special Reference to the Liver Damages. Fukuoka Acta Medicine, 71(1); 27-40, 1980

Examiner	Date Considered
----------	-----------------

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Rev. 2-32) U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Information Disclosure Statement by Applicant	ATTY. DOCKET NO.	SERIAL NO
	WAX017-185360C	To Be Assigned
	APPLICANT Zhang, Ting-Dong	
FILING DATE To Be Assigned	GROUP To Be Assigned	

		The Merck Index, 10th ed., Rahway (NJ), Merck & Co., Inc., 1983, page 117, entry 824
		Sun H.D. et al. The Therapeutical Effect of Ailing No. 1(As ₂ O ₃) on 32 cases with acute promyelocytic leukemia (APL). Chinese Union Journal of Traditional Medicine and Western Medicine, 12:170, 1992
		Shimotsoura, S. et al., "Studies on the antineoplastic actions of As ₂ O ₃ ," Shikwa Gakuho, Vol. 86, pages 1237-1253
		Venditti J.M., The National Cancer Institute Antitumor Drug Discovery Program, Current and Future Perspectives. A Commentary, Cancer Treatment Reports Vol. 67, No. 9, September, 1983
		Chemical Abstracts 130: 115060, 1999
		Zhang Peng et al., "APL Treatment with '713' - Clinical obsevation on 117 cases and mechanism study," The Academic Journal of Harbin Medical University, Issue 3, page 243, June, 1995 (English Translation)
		Zhang T. et al., "Clinical Analysis and Experimental Research on Ai-Ling I Medicine in Treating Acute Granulocytic Leukema, Chinese & Western Medicines Magazine, Vol. 4, No. 1, 1984 (English Translation)
		Chinese Medical Association, Heilongjiang Branch, "Letter on Historical Facts Regarding the Development of "Ai Ling No. 1" and the Clinical Use of Arsenic Trioxide in the Treatment of Acute Promyelocytic Leukemia and a Study of Its Mechanism," March 27, 1998 (English Translation)
		The Merck Index, 10th ed., Merck & Co., Rahway (NJ), 1983, page 1098, item #7479
		Forkner, C.E. et al., "Arsenic as a therapeutic agent in chronic myelogenous leukemia," The Journal of the American Medical Association, Vol. 97, No. 1, July 4, 1931, pages 3-5

Examiner	Date Considered
----------	-----------------

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.